Quest Diagnostics Q3 2024 Earnings Report
Key Takeaways
Quest Diagnostics reported a strong third quarter with an 8.5% increase in total revenue, including 4.2% organic growth. The company's performance was driven by new customer wins, expanded business with physicians and hospitals, and recent acquisitions. Due to contributions from recent acquisitions, the company has increased its 2024 revenue guidance and has maintained the midpoint of its adjusted EPS guidance despite the impact of Hurricane Milton in the fourth quarter.
Third quarter revenues increased by 8.5% compared to 2023.
Reported diluted earnings per share increased by 1.5% from 2023.
Adjusted diluted earnings per share increased by 3.6% from 2023.
Full year 2024 revenues are now expected to be between $9.80 billion and $9.85 billion.
Quest Diagnostics
Quest Diagnostics
Quest Diagnostics Revenue by Segment
Forward Guidance
The company updates its full year 2024 guidance. The updated guidance reflects the impact of recent acquisitions including LifeLabs as well as the impact from Hurricane Milton in the fourth quarter. The company projects the disruption from Hurricane Milton to negatively impact net revenues by approximately $15 million and EPS by approximately 8 cents in the fourth quarter.
Positive Outlook
- Net revenues are expected to be between $9.80 billion and $9.85 billion.
- Net revenues increase between 5.9% and 6.5%.
- Reported diluted EPS is expected to be between $7.60 and $7.70.
- Adjusted diluted EPS is expected to be between $8.85 and $8.95.
- Cash provided by operations approximately $1.3 billion
Challenges Ahead
- Hurricane Milton is projected to negatively impact net revenues by approximately $15 million in the fourth quarter.
- Hurricane Milton is projected to negatively impact EPS by approximately 8 cents in the fourth quarter.
- Restructuring and integration charges of $0.34
- Amortization expense of $0.85
- Other charges of $0.12